Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B-Reference-Cited by-同舟云学术

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

Published:2020-06-30 Issue:19 Volume:26 Page:5086-5091
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Carlino Matteo S.,Menzies Alexander M.,Atkinson Victoria,Cebon Jonathan S.^ORCID,Jameson Michael B.^ORCID,Fitzharris Bernard M.,McNeil Catriona M.^ORCID,Hill Andrew G.,Ribas Antoni,Atkins Michael B.,Thompson John A.,Hwu Wen-Jen,Hodi F. Stephen,Guminski Alexander D.,Kefford Richard,Wu Haiyan,Ibrahim Nageatte^ORCID,Homet Moreno Blanca,Long Georgina V.^ORCID

Funder

Merck Sharp & Dohme, a subsidiary of Merck & Co Inc, Kenilworth, NJ, USA

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Effect Waning in Immuno-oncology Health Technology Assessments: A Review of Assumptions and Supporting Evidence with Proposals to Guide Modelling;PharmacoEconomics;2024-08-23

2. Recent advances in immunotherapy and its combination therapies for advanced melanoma: a review;Frontiers in Oncology;2024-07-16

3. The treatment of advanced melanoma: Current approaches and new challenges;Critical Reviews in Oncology/Hematology;2024-04

4. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis;Cancers;2024-01-13

5. Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy;3 Biotech;2023-11-21